In this GEN webinar, Dr. Wen Xue will present a modular delivery strategy for homology-directed repair by combining lipid nanoparticle delivery of Cas9 mRNA with adeno-associated viruses (AAV) encoding a sgRNA and a repair template.
Immune medicines, across cancers, infectious disease, and inflammatory disease, hold our closest promise to lasting curative therapies. In this sponsored webinar, IsoPlexis and various researchers will speak about the shift in space and time towards ‘Smaller’ to target our most powerful single cells, in order to accelerate timelines for finding these cures.
In this webinar from GEN and The CRISPR Journal, T.J. Cradick, PhD, —who was until recently head of genome editing at CRISPR Therapeutics—will introduce how genome editing is used to engineer cell therapies.
In TODAY's GEN webinar, sponsored by Accellix, our distinguished speaker will describe the simple, but elegant production process his organization uses when manufacturing hematopoietic stem cell (HSC) therapies, and discuss many of the special considerations involved in the analytical development and production of various cell therapies.
In this GEN webinar, sponsored by PerkinElmer, our expert speakers, who are leading investigators in the field of cell and gene therapy, will discuss emerging gene-edited and engineered cell therapies for cancer, as well as the next generation of AAV vectors for human gene therapy.
In this GEN webinar, sponsored by Horizon Discovery, we will provide a field overview of how iPSCs, coupled with genome editing, hold the potential to expand our understanding of human diseases further, and facilitate the development of new therapies.
During this presentation, which is part of TriLink BioTechnologies gene editing and cell therapy webinar series, Dr. Gaudelli will discuss how her group has transformed off-the-shelf base editors from a technology developed in academia to a promising therapeutic tool through engineering, screening, and directed evolution.
In this recorded GEN Live event, sponsored by PerkinElmer, we discussed the state of gene therapy, the rise of AAV, and the safety issues that need to be addressed going forward.
In this GEN webinar, sponsored by Lonza, we will hear about a high-throughput platform for CRISPR-Cas9 gene editing in primary human cells for the robust functional interrogation of complex biological processes and disease states. We also learn about the clinically relevant scale of gene-editing, platforms, and approaches, process development considerations for bringing these gene-edited therapies to the clinic.
In this GEN webinar, sponsored by Wyatt Technology, we will discuss how dynamic light scattering (DLS) and multi-angle light scattering combined with size exclusion chromatography (SEC-MALS) or field-flow fractionation (FFF-MALS) characterize AAV, LV, and other gene delivery vectors.